

PRESS RELEASE

Cordlife invests SGD 8.4 million in CellResearch Corporation to enhance value proposition of Umbilical Cord Lining banking service

- ***Investment to be made via subscription of Class A Redeemable Convertible Note and purchase of ordinary shares***
- ***Funds to be used to further clinical development of advance wound healing technology with umbilical cord lining***
- ***Transactions strengthen strategic alliance with CellResearch Corporation and enhance value add of Cordlife's clinical and quality assurance capacity***

Singapore, 1 February 2016 – Cordlife Group Limited (“Cordlife”, and together with its subsidiaries, the “Group”), a mother and child consumer healthcare company, is pleased to announce that it has extended its strategic alliance with CellResearch Corporation Pte. Ltd. (“CRC”) via an SGD 8.4 million investment which will be funded by internal resources. Cordlife entered into a strategic alliance agreement with CRC in 2010 to provide umbilical cord lining (“UCL”) banking service leveraging on CRC’s technology of harvesting stem cells from the amniotic membrane of the umbilical cord.

The Group will subscribe for a Class A Redeemable Convertible Note (“RCN”) maturing 3 years from the issue date in the principal amount of SGD 4.2 million from CRC. The yielding interest is at a rate of three month SIBOR plus 7% per annum payable annually in arrears. In addition, the Group will purchase 4,167,858 ordinary shares (“Sale Shares”) in CRC from the founders of CRC (“Vendors”) for SGD 4.2 million (the “Consideration”) with an adjustment mechanism for Cordlife to, among others, either receive additional ordinary shares in CRC from the Vendors for SGD 1 or sell the Sale Shares back to the Vendors at a price of the Consideration plus 7% of the Consideration compounded over 3 years, if a net profit target is not met for the year ending 31 December 2018.

CRC has entered into a Services and Research Collaboration Agreement with the University of Colorado School of Medicine and ClinImmune Labs in June 2015 with the aim to reach a point where they can embark on US FDA approved trials for the treatment of diabetic wounds using UCL stem cells. The proceeds from the RCN will be primarily

used to accelerate the clinical development of the advanced wound healing technology. This will significantly enhance the value proposition of Cordlife's UCL banking service in existing markets such as India, Hong Kong, Singapore, Thailand, Philippines, Malaysia, Indonesia and China.

Mr Jeremy Yee, Executive Director and Chief Executive Officer of Cordlife said: "This investment not only aligns the strategic interest between Cordlife and CRC, but also significantly enhances Cordlife's clinical and quality assurance capacity as we are able to leverage on reputable research institutions and top-notch research facilities. We are also exhilarated to be able to contribute to the clinical development of CRC's advanced wound healing technology as this will further validate and strengthen our core business. With this, we are poised to capitalise on the tremendous growth opportunities of the cord blood and cord lining banking market."

Mr Gavin Tan, Chief Executive Officer of CRC said: "Since 2010, our strategic alliance with Cordlife has grown from strength to strength. We are delighted with this latest development as it narrows the gap between the banking of umbilical cord lining stem cells and their broader therapeutic uses. Together with Cordlife and our clinical development partners, we are accelerating the development of the Global Cord Registry and CRC's stem cell technology to benefit patients, customers and the broader medical community."

- The End -

ABOUT CORDLIFE GROUP LIMITED (Bloomberg stock code: CLGL)

Incorporated in May 2001, Cordlife Group Limited (“Cordlife”, and together with its subsidiaries, the “Group”), is a consumer healthcare company catering to the mother and child segment and a leading cord blood and cord lining banking services provider. Amongst the first private cord blood banks in Asia, Cordlife has the largest market share of private cord blood banks in Singapore, Indonesia and the Philippines¹. In Hong Kong and India, it is amongst the top three market leaders for private cord blood banks.

Cordlife, through its collaborative relationships and arrangements with major private hospitals and clinics such as Thomson Medical and Parkway East Hospital, has continued to increase public awareness of its cord blood banking service in Singapore. Overseas, Cordlife also acquired a 19.92% stake in October 2013, which was subsequently increased to approximately 31.81% in December 2013, in StemLife Berhad (“StemLife”). StemLife is a fully licensed cord blood banking facility with the Ministry of Health Malaysia and is currently listed on the ACE Market of Bursa Malaysia. On 12 November 2015, Cordlife announced that it acquired an additional 1.21% of the issued and paid-up capital of StemLife, to further increase its interest in the issued and paid-up capital of StemLife from 31.81% to approximately 33.03%, and that pursuant to the Malaysian Code on Take-Overs and Mergers, 2010 and the Capital Markets and Services Act, 2007, of Malaysia, Cordlife has extended a mandatory take-over offer to acquire all the remaining StemLife Shares not already owned by Cordlife (the “Offer Shares”). As announced by the Company on 1 February 2016, the Company owns or has acquired additional Offer Shares approximately 89.60% of the issued and paid-up capital of StemLife as of 1 February 2016.

Cordlife has been accredited since 2005 by AABB (formerly known as the American Association of Blood Banks), an association involved in the field of transfusion medicine and cellular therapies. The Group is one of the first private cord blood banks in Singapore and amongst the first in Hong Kong to have released cord blood units for transplants and other therapeutic use. In Singapore, Cordlife was the first private cord blood bank to release cord blood units for the treatment of cerebral palsy. In addition, in April 2013, Cordlife became the first private cord blood bank in Asia to have launched SEPAX^{®2}, a Swiss-made FDA-approved, GMP compliant automated stem cell processing system that maximises automation while ensuring consistently high cell recoveries. Cordlife also has a strategic alliance with CordLabs Asia Pte. Ltd., a wholly-owned subsidiary of CellResearch Corporation Pte. Ltd., which gives the Group the exclusive rights to market their technology in relation to the provision of human postnatal cord lining storage services and training and the transfer of the know-how, in India, Indonesia, Malaysia, Philippines, Singapore, Hong Kong, Thailand and certain territories in the People’s Republic of China.

Cordlife’s track record has won the Group many accolades and awards, including: Best Medical Service Award 2010 by Capital CEO Supreme Brand Awards; Top Pregnant/Baby Products Award 2011 by Pregnancy Magazine; Outstanding Financial Strength Cord Blood Bank 2012 by Quamnet Outstanding Enterprise Awards; Most Popular Brand Award 2010 – The Most Popular Cord Blood Bank by TVB Weekly; U-Choice Lifestyle Brand Award 2010 by Metroinfo FM99.7; Baby & Kid Brands Awards Year 2013, “My Favourite Cord Blood Bank” by Hong Kong Economic Times; 2014 Most Popular Stem Cell Bank Reader’s Choice by Child Magazine; 2013-2014 MyBB Parent-Child Favorite Cord Blood and Umbilical Cord Bank Company and Baby Kingdom Top 10 Family Brand Award 2012². In

¹ Source : Deloitte & Touche Financial Advisory Services Limited report, October 2014

² Awarded to Cordlife (Hong Kong) Limited

October 2012, Cordlife was awarded the prestigious SIAS Investors' Choice Awards as runner-up in the "Most Transparent Company Award 2012" New Issues Category. In August 2013, we were presented with Merit Award for the Singapore Corporate Awards 2013, "Best Investor Relations Award". In November 2013, Cordlife was named the "Most Transparent Company 2013" in the Retail & Household Goods Category and Mainboard Small Caps Category at the 14th SIAS Investors' Choice Awards. In October 2015, named as the Runner-up of the 16th SIAS Investors' Choice Award, Singapore Corporate Governance Award (SCGA) 2015, Mid and Small Category. Cordlife was also honoured by Forbes Asia as one of the "Best Under a Billion" companies at an awards ceremony and dinner held in November 2015.

ABOUT CELLRESEARCH CORPORATION PTE LTD ("CRC")

Founded in Singapore in 2002 by a group of clinician scientists and investors, CRC is the pioneer and global leader in Cord Lining Stem Cells for Stem Cell Regenerative Medicine and Therapy. Both an inventor and market leader in this space, CRC is at its core a Cord Lining Stem Cell Technology Asset Manager, with its main business lines comprising the banking of Cord Lining Stem Cells, development of cosmeceuticals in the form of their product, Calecim[®], and advanced wound care, through their CorLinEx[™] developments. CRC has multiple research collaborations globally to enhance the potential of the cord lining stem cell technology. CRC has worked to obtain a vast range of patents in over 39 countries worldwide for their innovations and products.

CRC also owns one of the world's largest private skin, scar and keloid cell libraries which provides high quality primary cell strains, culture media and research service support to researchers and corporations worldwide.

CRC owns and manages the Global Cord Registry[™] ("GCR"), where parents who have banked their child's cord lining stem cells with CRC's licensed partners are ensured the banked stem cells have been processed properly at a licensed cord blood/tissue bank, and have an assurance that the banked stem cells are licensed to be used for therapies in the future. Donors on GCR will also be able to obtain updates on therapeutic advancements and applications of the cord lining stem cells.

ISSUED ON BEHALF OF	: Cordlife Group Limited
BY	: Financial PR Pte Ltd 4 Robinson Road #04-01 The House of Eden Singapore 048543
CONTACT	: Mr Kamal Samuel / Mr Ngo Yit Sung
OFFICE	: 6438-2990
EMAIL	: kamal@financialpr.com.sg / yitsung@financialpr.com.sg
